摘要
目的探讨米非司酮治疗围绝经期子宫肌瘤的临床疗效及安全性。方法选取2017年8月至2019年1月间上海复旦大学附属中山医院青浦分院收治的142例围绝经期子宫肌瘤患者为研究对象。采用随机数表法分为A组和B组,每组71例。A组患者给予亮丙瑞林治疗,B组患者给予米非司酮治疗。观察两组患者治疗前后子宫体积、最大子宫肌瘤体积和血红蛋白水平,比较两组患者临床效果及不良反应发生率。结果治疗前,两组患者子宫体积、最大子宫肌瘤体积和血红蛋白水平比较,差异无统计学意义(P> 0. 05)。治疗后,两组患者子宫体积和最大子宫肌瘤体积均显著降低,血红蛋白均显著升高,且B组与同期A组比较,上述指标均显著改善,差异均有统计学意义(均P <0. 05)。B组治疗有效率为91. 6%,显著高于A组,差异有统计学意义(P <0. 05)。两组患者不良反应发生率比较,差异无统计学意义(P> 0. 05)。结论米非司酮治疗围绝经期子宫肌瘤患者临床效果显著,临床安全性良好,具有临床推广价值。
Objective To investigate the clinical efficacy and safety of mifepristone in the treatment of perimenopausal patients with uterine fibroids.Methods A total of 142 perimenopausal women with uterine fibroids who were treated at Sun Yat-sen Hospital Affiliated to Fudan University from August 2017 to January 2019 were selected as subjects.The patients were divided into group A and group B with 71 patients in each group by random number table.Group A was given leuprolide treatment and group B was given mifepristone.The uterus volume,maximum uterine fibroid volume and hemoglobin level before and after treatment were observed.The clinical efficacy and adverse reactions in the two groups were statistically analyzed.Results There was no significant difference in volume of uterus,the volume of maximal uterine fibroids and hemoglobin level between the two groups before the treatment(P>0.05).After the treatment,uterus volume,maximum uterine fibroid volume decreased and hemoglobin level increased obviously in both groups(all P<0.05).There were great difference in the above levels between the two groups after the treatment(all P<0.05).The effective rate was 91.6%for group B which was significantly higher than for group A(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Mifepristone is effective in the treatment of perimenopausal women with uterine fibroids with good clinical safety and clinical value.
作者
张红
俞菊珍
潘培芳
ZHANG Hong;YU Ju-zhen;PAN Pei-fang(Department of Gynecology,Qingpu Branch,Sun Yat-sen Hospital Affiliated to Fudan University,Shanghai 201700,China)
出处
《中国肿瘤临床与康复》
2019年第5期584-586,共3页
Chinese Journal of Clinical Oncology and Rehabilitation